---
title: A Study of Axitinib in Advanced Carcinoid Tumors
nct_id: NCT01435122
overall_status: COMPLETED
phase: PHASE2
sponsor: H. Lee Moffitt Cancer Center and Research Institute
study_type: INTERVENTIONAL
primary_condition: Carcinoid Tumor
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01435122.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01435122"
ct_last_update_post_date: 2018-10-02
last_seen_at: "2026-05-12T06:23:02.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study of Axitinib in Advanced Carcinoid Tumors

**Official Title:** A Phase II Study of Axitinib in Advanced Carcinoid Tumors

**NCT ID:** [NCT01435122](https://clinicaltrials.gov/study/NCT01435122)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Collaborators:** National Comprehensive Cancer Network, Pfizer
- **Conditions:** Carcinoid Tumor
- **Start Date:** 2011-10-25
- **Completion Date:** 2018-02-13
- **CT.gov Last Update:** 2018-10-02

## Brief Summary

The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing. Researchers also want to find out if Axitinib is safe and tolerable.

## Detailed Description

This is a bi-institutional, prospective phase II, open-label study. The target population is comprised of adult patients with histologically confirmed unresectable or metastatic carcinoid tumors. Carcinoid tumors are defined as well to moderately differentiated neuroendocrine tumors of the digestive tract and lungs. Patients with metastatic carcinoid tumors of unknown primary as well as rare primaries (renal, ovarian, thymic, hepatic) will also be eligible. Patients will be drawn from two institutions Moffitt Cancer Center (MCC) and The University of California, San Francisco (UCSF).

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Locally unresectable or metastatic well-and moderately-differentiated (low- or intermediate- grade) neuroendocrine tumors of the aerodigestive tract (e.g. foregut, midgut, and hindgut) and unknown primary site as well as rare primary sites (renal, ovarian, thymic, hepatic); Otherwise known as typical or atypical carcinoid tumors
* Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) Criteria
* Functional or nonfunctional tumors allowed
* Evidence of progressive disease within 12 months of study entry
* Adequate hepatic function: total bilirubin ≤1.5 x upper limit of normal (ULN)mg/dl; aspartic transaminase (AST) ≤2.5 x ULN (≤5 x ULN if attributable to liver metastases)
* Adequate renal function: serum creatinine ≤ 1.5 x ULN
* Adequate bone marrow function: absolute neutrophil count ≥ 1,500/mm³; platelets ≥75,000/mm³
* Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels ≤1.5 x ULN (unless patients receiving coumadin anticoagulation in which case a stable international normalization ration (INR) of 2-3 is required).
* Urine protein \<2+proteinuria (or \<2 g proteinuria /24 hr)
* Prior somatostatin-analog therapy required in patients with midgut carcinoid tumors
* Minimum 4 weeks since completion of prior treatment (investigational or other). Prior treatment with chemotherapy, radiotherapy, hepatic artery embolization, surgery or other therapeutic agents is allowed.
* Treatment related toxicity should have returned to baseline and/or ≤grade 1 prior to study treatment.
* Prior or concurrent therapy with somatostatin analogs is permitted for the control of hormone-mediated symptoms, provided patient has been on a stable dose for at least 2 months and progressive disease on somatostatin analogs (SSTa) has been documented
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to treatment.
* Ability to sign informed consent
* Willingness and ability to comply with scheduled visits, laboratory tests and other study procedures

Exclusion Criteria:

* Poorly differentiated, high-grade (e.g. small cell or large cell) neuroendocrine carcinomas are excluded.
* Pancreatic neuroendocrine tumors (NETs), paragangliomas, pheochromocytomas and medullary thyroid cancers are excluded.
* Adenocarcinoid tumors and goblet cell carcinoid tumors are excluded.
* Prior antiangiogenic therapy with a dedicated vascular endothelial growth factor (VEGF) pathway inhibitor
* Clinically apparent central nervous system metastases
* Any of the following within 12 months prior to study: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack
* Deep venous thrombosis or pulmonary embolism within 6 months of study
* Major surgery 4 weeks prior to enrollment
* Inability to take oral medication or prior surgical procedures affecting absorption (including total gastric resection)
* Active gastrointestinal bleeding, if transfusion dependent
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
* History of pulmonary hemorrhage or evidence of significant hemoptysis
* History of serious non-healing wound, ulcer, or bone fracture within the past 28 days
* Pre-existing thyroid abnormality allowed provided thyroid function can be controlled with medication.
* Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, clarithromycin, indinavir, saquinavir, ritonavir, nelfinavir, etc.)
* Current use or anticipated need for treatment with drugs that are known inducers of CYP3AR or CYP1A2 (i.e carbamazepine, dexamethasone, omeprazole, phenobarbital, phenytoin, rifampin, St. John's Wart, etc.)
* Uncontrolled serious medical or psychiatric illness. Patients with a "currently active" second malignancy other than non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer (staged pathological tumor-2 (pT2) with Gleason Score ≤ 6 and postoperative prostatic specific antigen (PSA) \< 0.5 ng/mL), or other adequately treated carcinoma-in-situ are ineligible. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥3 years.
* Pregnant or lactating women, or adults of reproductive potential who are not using effective birth-control methods.
* Prior antitumor therapy within 4 weeks of enrollment (with exception of somatostatin analogs)
* Liver-directed therapy within 2 months of enrollment. Prior treatment with radiotherapy (including radio-labeled spheres and/or cyberknife, hepatic arterial embolization (with or without chemotherapy) or cryotherapy/ablation is allowed if these therapies did not affect the areas of measurable disease being used for this protocol or if progressive disease can be documented in the previously treated area.
* Recent infection requiring systemic anti-infective treatment that was completed ≤14 days prior to enrollment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection)
* Uncontrolled hypertension (blood-pressure \>140/90). Patient with baseline hypertension may be eligible after initiation of antihypertensive therapy.
```

## Arms

- **Axitinib Administration** (EXPERIMENTAL) — The investigational drug used in this study is axitinib, and is available as tablets.

You will take the tablet orally with food. Doses should be taken around 12 hours apart continuously, without scheduled breaks. If you vomit anytime after taking a dose do not take another tablet to "make up the dose" but instead continue taking your next dose as planned.

Any missed dose may be taken late (up to 3 hours before the next scheduled dose); otherwise it should be skipped. If doses are missed or vomited, please keep track of this and report at your next visit.

## Interventions

- **Axitinib** (DRUG) — Axitinib Administration as outlined in Arm description

## Primary Outcomes

- **Rate of Progression Free Survival (PFS)** _(time frame: 12 Months)_ — Progression-free survival rate at 12 months. PFS: determined as the time from administration of the initial dose of axitinib until objective tumor progression using Response Evaluation Criteria In Solid Tumors (RECIST), or death. Progressive Disease (PD) Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. Stable Disease (SD): Neither sufficient shrinkage to qualify for Partial Response (PR) nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
- **Median Progression Free Survival** _(time frame: Up to 36 Months)_ — Post follow-up progression free survival at time of analysis.

## Secondary Outcomes

- **Tumor Response Rate** _(time frame: 12 Months)_
- **24 Month Overall Survival (OS) Rate** _(time frame: 24 months)_
- **Time to Treatment Failure** _(time frame: 12 Months)_
- **Occurrence of Possibly Related Adverse Events (AEs)** _(time frame: 12 Months)_

## Locations (2)

- University of California San Francisco (UCSF), San Francisco, California, United States
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of california san francisco (ucsf)|san francisco|california|united states` — added _(2026-05-12)_
- `locations.h. lee moffitt cancer center and research institute|tampa|florida|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01435122.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01435122*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*